Eli Lilly, Boehringer Diabetes Drug Faces FDA Roadblock
The U.S. Food and Drug Administration has said it observed "deficiencies" at the site where a new diabetes drug developed by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. will...To view the full article, register now.
Already a subscriber? Click here to view full article